NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Poxel S.A (PA: POXEL)

 
POXEL Technical Analysis
1
As on 16th Oct 2024 POXEL STOCK Price closed @ 0.33 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

POXELSTOCK Price

Open 0.34 Change Price %
High 0.34 1 Day N/A N/A
Low 0.32 1 Week 0.00 0.00
Close 0.33 1 Month 0.00 0.00
Volume 160982 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
PA France Most Active Stocks
FTI 5.91 -1.66%
VIEDS 0.72 4.35%
ALNRG 0.01 %
ORA 10.23 %
LAT 0.01 %
ALVER 0.01 %
CGG 0.69 -2.82%
ACA 14.06 %
ALHYG 0.01 %
TTE 59.41 %
 
PA France Top Gainers Stocks
2MX 7.46 8.43%
ATA 0.13 8.33%
ATA 0.13 8.33%
ATA 0.13 8.33%
ATA 0.13 8.33%
ATA 0.13 8.33%
ALP 21.50 6.44%
ALP 21.50 6.44%
ALANT 4.68 6.36%
VIEDS 0.72 4.35%
 
PA France Top Losers Stocks
AKOM 4.06 -37.05%
AKOM 4.06 -37.05%
FPN 0.02 -33.33%
MLMON 0.88 -12.00%
PROL 0.24 -7.69%
LFDE 44.20 -7.14%
HOP 14.70 -4.85%
STM 44.40 -4.02%
STM 44.40 -4.02%
STM 44.40 -4.02%
 
 
POXEL
Daily Charts
POXEL
Intraday Charts
Whats New @
Bazaartrend
POXEL
Free Analysis
 
POXEL Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
POXEL Forecast October 2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
POXEL Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
POXEL Forecast2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
POXEL Other Details
Segment EQ
Market Capital 168358704.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
POXEL Address
POXEL
 
POXEL Latest News
 
Your Comments and Response on Poxel S.A
 
POXEL Business Profile
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France. Address: Immeuble Le Sunway, Lyon, France, 69007
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service